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57 ABSTRACT 
Novel texaphyrin compounds having improved functional 
ization are described. Metal complexes of these compounds 
are active as photosensitizers for the generation of singlet 
oxygen and thus are potentially useful for treatments per 
formed with singlet oxygen. Several of the metallotexaphy 
rin complexes absorb light in the physiologically important 
range of 690-880 nm. The complexes form long-lived triplet 
states and thus may act as efficient photosensitizers for 
generation of singlet oxygen. 
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1. 
METHODS OF PRODUCING SNGLET 
OXYGEN USING COMPOUNDS HAVING 
IMPROVED FUNCTIONALIZATION 
This application is a continuation application of U.S. 
application Ser. No. 08/459,333, filed Jun. 2, 1995, now U.S. 
Pat. No. 5.599,929, the entire text of which is incorporated 
herein by reference. 
FELD OF THE INVENTION 
The present invention relates to the field of expanded 
porphyrins, in particular, to texaphyrins having improved 
functionalization. 
BACKGROUND OF THE INVENTION 
Certain texaphyrin compounds are described in U.S. Pat. 
Nos. 4935,498, 5.162,509, 5.252,720, 5,272,142 and 5.256, 
399, each of which is incorporated by reference herein. 
"Texaphyrin" refers to a particular "expanded porphyrin" 
pentadentate macrocyclic ligand. The compound is capable 
of existing in both its free-base form and of supporting the 
formation of a 1:1 complex with a variety of metal cations, 
such as Cd", Hg. In", y, Nd". Eu", Sm", La", Lu'. 
Gd", and other cations of the lanthanide series that are too 
large to be accommodated in a stable fashion within the 20% 
smaller tetradentate binding core of the well-studied por 
phyrins. 
Large, or "expanded" porphyrin-like systems are of inter 
est for several reasons: They could serve as aromatic ana 
logues of the better studied porphyrins or serve as biomi 
metic models for these or other naturally occurring pyrrole 
containing systems. In addition, large pyrrole-containing 
systems offer possibilities as novel metal binding macro 
cycles. For instance, suitably designed systems could act as 
versatile ligands capable of binding larger metal cations 
and/or stabilizing higher coordination geometries than those 
routinely accommodated within the normally tetradentate 
ca. 2.0 A radius porphyrin core. The resulting complexes 
could have important application in the area of heavy metal 
chelation therapy, serve as contrast agents for magnetic 
resonance imaging (MRI) applications. act as vehicles for 
radioimmunological labeling work, or serve as new systems 
for extending the range and scope of coordination chemistry. 
The desirable properties of texaphyrins are: 
1) appreciable solubility, particularly in aqueous media; 
2) biolocalization in desired target tissue; 
3) low intrinsic toxicity; 
4) the ability to attach to solid matrices; 
5) the ability to be attached to biomolecules; 
6) efficient chelation of divalent and trivalent metal cat 
1OnS; 
7) absorption of light in the physiologically important 
region of 690-880 nm; 
8) high chemical stability; 
9) ability to stabilize diamagnetic complexes that form 
long-lived triplet states in high yield and that act as 
efficient photosensitizers for the formation of singlet 
oxygen; 
10) ability to chelate Gd(III) for magnetic resonance 
imaging; 
11) a redox potential lower than that of oxygen for use as 
a radiosensitizer. 
One of the disadvantages of the texaphyrin metal com 











In" complexes of the basic texaphyrin have half-lives for 
decomplexation and/or ligand decomposition of about 3 
weeks in 1:1 methanol-water mixtures. While such stability 
is adequate for some in vitro or in vivo applications, a 
greater degree of stability in aqueous solution is desirable. 
For example, a desired solution-phase shelf life of 2-3 years 
would facilitate the formulation of texaphyrin metal com 
plexes as pharmaceutical products. The new molecules of 
the present invention address the problems of demetallation 
of the texaphyrin metal complex and the susceptibility of the 
imine bonds of the macrocycle to hydrolysis. The solution to 
these problems is expected to provide a texaphyrin which 
has a more desirable shelf life. 
SUMMARY OF THE INVENTION 
The present invention seeks to solve the above problems 
by providing texaphyrin metal complexes having improved 
functionalization compared to those previously described. 
The improved functionalization is two-fold: firstly, addition 
of electron-donating groups to positions 2, 7, 12, 15, 18 
and/or 21 of the macrocycle contributes electrons to the 
aromatic Tc system of the macrocycle which stabilizes the 
metal complex to demetallation and stabilizes the imine 
bonds to hydrolysis; and secondly, the addition of electron 
withdrawing groups to positions 15 and/or 18 renders the 
macrocycle more readily reduced, i.e. the redox potential 
will be lower and the macrocycle will more readily gain an 
electron to form a radical. The addition of substituents to the 
12 and 21 positions of the macrocycle also offers steric 
protection for the imine bonds against possible in vivo 
enzyme hydrolysis. Thus, the macrocycles of the present 
invention represent molecules where an attempt has been 
made to optimize their structure and properties in terms of 
imine bond stabilization and low redox potential. properties 
that are expected to be important for radiosensitization as 
well as other applications. 
Exemplary electron-donating groups that may be 
employed in the practice of the invention include, among 
others, amino, alkylamino, hydroxyl, acylamino, alkoxy, 
acyloxy, alkyl, aryl, and alkenyl. Electron-withdrawing 
groups include halide other than iodide, haloalkyl other than 
iodoalkyl, formyl, acyl carboxylic acid. ester, acyl chloride, 
sulfonic acid, and nitro, among others. Other potential 
electron-donating or withdrawing groups will be apparent to 
one of skill in the art in light of the present disclosure. 
In certain embodiments, the present invention provides a 
texaphyrin having the structure: 
Z 
R 
M is H. a divalent metal cation, or a trivalent metal cation. 
R-R, R and Rs are independently hydrogen, halide, 




hydroxyalkyl, oxyalkyl, oxyhydroxyalkyl, saccharide, 
carboxy, carboxyalkyl, carboxyamidealkyl, a site 
directing molecule, a catalytic group, or a couple to a 
site-directing molecule or to a catalytic group. 
R and R are independently selected from the groups of 
R-R. R. and Rs with the proviso that the halide is 
other than iodide and the haloalkyl is other than 
iodoalkyl. 
Rs and Ro-R are independently hydrogen, alkyl, aryl. 
hydroxyalkyl oxyalkyl, oxyhydroxyalkyl, 
carboxyalkyl, carboxyamidealkyl or a couple to a 
saccharide. to a site-directing molecule or to a catalytic 
group. 
For this invention. at least one of Rs. R. R. Ro R and 
R is other than hydrogen. 
The charge, Z is an integer value less than or equal to 5. 
Here, as would be apparent to one skilled in the art, the 
charge Z would be adjusted so as to account for the choice 
of metal, M. the pH under consideration, and the substituents 
R-R. For instance, if R =carboxyl and R-R-alkyl and 
the metal M=Gd", and the solution is pH=7 (so that 
R=CO-), the charge Z would be zero. The charge would 
be negative when substituents have a sufficient number of 
negative charges, for example, when a substituent is an 
oligonucleotide. The charge would be +5, for example, when 
the M is Gd" and the net charge of a substituent(s) is three 
positive charges. 
An aspect of the present invention is an embodiment 
where a substituent may be an electron-donating group. In 
this case, R-R and R-R are independently hydrogen, 
hydroxyl alkyl, aryl, hydroxyalkyl, oxyalkyl, 
oxyhydroxyalkyl, saccharide, carboxyalkyl, 
carboxyamidealkyl, a site-directing molecule, a catalytic 
group. or a couple to a site-directing molecule or to a 
catalytic group. R. and Ro-R2 are independently 
hydrogen, alkyl, aryl, hydroxyalkyl, oxyalkyl, 
oxyhydroxyalkyl, carboxyalkyl, carboxyamidealkyl or a 
couple to a saccharide, to a site-directing molecule or to a 
catalytic group. At least one of R. R. R. Ro R and R12 
is other than hydrogen and Z is an integer less than or equal 
to 5. 
In another embodiment of the present invention, R or R 
may have an electron-withdrawing group. In that case, 
R-R, R and Rs are independently hydrogen, halide, 
hydroxyl, alkyl, aryl, haloalkyl, nitro, formyl, acyl, 
hydroxyalkyl, oxyalkyl oxyhydroxyalkyl, saccharide, 
carboxy. carboxyalkyl, carboxyamidealkyl, a site-directing 
molecule, a catalytic group, or a couple to a site-directing 
molecule or to a catalytic group. R. and Ro-R are 
independently hydrogen, alkyl, aryl, hydroxyalkyl, 
oxyalkyl oxyhydroxyalkyl, carboxyalkyl, carboxyamid 
ealkyl or a couple to a saccharide, to a site-directing mol 
ecule or to a catalytic group. R and R are independently 
hydrogen, halide other than iodide, formyl, acyl, carboxy, or 
nitro, where at least one of R and R is other than hydrogen 
and Z is an integer less than or equal to 5. 
A couple may be an amide, disulfide, thioether, or ether 
covalent bond. A site-directing molecule may have binding 
specificity for localization to a treatment site. 
It is contemplated that the texaphyrins of the present 
invention are useful in a variety of applications including 
use as a photodynamic therapy agent, as a magnetic reso 









hydrolysis, and for DNA photocleavage. The use of a 
texaphyrin diamagnetic-metal complex having a substituent 
at the 2, 7, 12. 15, 18 and/or 21 position and an absorption 
range from about 730 to about 770 nanometers includes the 
65 
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following methods which take advantage of the ability of 
these compounds to produce singlet oxygen: i) a method of 
deactivating a retrovirus or enveloped virus in an aqueous 
fluid, the method comprising the steps of adding said texa 
phyrin metal complex to said aqueous fluid and exposing the 
mixture to light to effect the formation of singlet oxygen; ii) 
a method of producing light-induced singlet oxygen com 
prising subjecting said texaphyrin metal complex to light in 
the presence of oxygen; iii) a method of photosensitization 
comprising photoirradiating said texaphyrin; iv) a method of 
DNA light-induced photocleavage comprising placing said 
texaphyrin in contact with the RNA or DNA and photoirra 
diating said texaphyrin; and v) a method of treating a host 
harboring atheroma or neoplastic tissue comprising admin 
istering to the host an effective amount of said texaphyrin 
complex, the complex exhibiting selective biolocalization in 
the atheroma or neoplastic tissue relative to surrounding 
tissues, and photoirradiating the texaphyrin complex in 
proximity to the atheroma or neoplastic tissue. 
Further aspects of the present invention include the use of 
a texaphyrin paramagnetic-metal complex having a substitu 
ent at the 2.7. 12. 15, 18 and/or 21 position in the following 
methods which take advantage of the high relaxivity of these 
compounds: i) a method of enhancement of relaxivity com 
prising the administration of said texaphyrin; ii) a method of 
magnetic resonance image enhancement comprising admin 
istering to a subject an effective amount of said texaphyrin 
followed by MR imaging of the subject; iii) a method of 
detection of atheroma or neoplastic tissue in a subject 
comprising administering to the subject said texaphyrin in 
an amount effective to enhance a magnetic resonance image 
and detecting the atheroma or neoplastic tissue by MR 
imaging of said subject; iv) a method of imaging an organ 
in a subject comprising administering to the subject said 
texaphyrin in an amount effective to enhance a magnetic 
resonance image of the organ and detecting the organ by MR 
imaging of said subject; v) a method of imaging an atheroma 
in a subject comprising administering to the subject said 
texaphyrin in an amount effective to enhance a magnetic 
resonance image of the atheroma and detecting the atheroma 
by MR imaging of said subject; and vi) a method of RNA 
hydrolysis comprising placing said texaphyrin in contact 
with the RNA. 
A method of treating a host harboring atheroma or neo 
plastic tissue is also an aspect of the present invention, such 
method comprising administering to the host as a first agent 
a texaphyrin detectable-metal complex of the present 
invention, said complex exhibiting selective biolocalization 
in the atheroma or neoplastic tissue relative to surrounding 
tissue; determining localization sites in the host by reference 
to such texaphyrin-detectable metal complex; administering 
to the host as a second agent a texaphyrin diamagnetic-metal 
complex having a substituent at the 2. 7, 12. 15, 18 and/or 
21 position and having essentially identical biolocalization 
property and exhibiting the ability to generate singlet oxy 
gen upon exposure to light; and photoirradiating the second 
agent in proximity to said atheroma or neoplastic tissue. 
The present invention provides a method of radiation 
therapy for a host harboring atheroma or neoplastic tissue, 
the method comprising administering to the host a texaphy 
rin of the present invention, and administering ionizing 
radiation to the host in proximity to the atheroma or neo 
plastic tissue. The radiation may be administered either 
before or after administration of the texaphyrin. The texa 
phyrin exhibits greater biolocalization in the atheroma or 
neoplastic tissue relative to surrounding tissues and has 
radiosensitization properties. An additional step may be 
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included, the step being the determination of localization 
sites of the atheroma or neoplastic tissue in the host by 
monitoring texaphyrin concentrations. 
One skilled in the art would recognize in light of the 
present disclosure that sapphyrin-conjugated texaphyrin 
metal complexes may be used in methods for generating 
singlet oxygen. Sapphyrin compounds are disclosed in U.S. 
Pat. Nos. 5,159.065 and 5,120,411 which are incorporated 
by reference herein. 
Texaphyrin metal complexes having increased solution 
phase stability are expected to be more stable in vivo. 
Increased stability achieved via specific, designed modifi 
cations of the texaphyrin skeleton could give rise to products 
with modified biolocalization properties. Selective targeting 
would improve the efficacy and utility of texaphyrins as 
diagnostic ortherapeutic agents for the range of applications 
discussed herein. 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS 
The present invention involves metal complexes of texa 
phyrins having a substituent(s) at the 2, 7, 12, 15, 18 and/or 
21 position(s) of the texaphyrin macrocycle and the synthe 
sis and uses thereof. The nomenclature as used herein 
defines a substituent Rattached to position 2, Rattached 
to position 7. Rs attached to position 12, R attached to 
position 15, Ro attached to position 18 and Rio attached to 
position 21 of the macrocycle. The following structure 
shows a correlation of the IUPAC nomenclature for the 
positions of the atoms around the periphery of the macro 








Substituents at the RandR positions on the B (benzene 
ring) portion of the macrocycle are incorporated into the 
macrocycle by their attachment to ortho-phenylenediamine 
in the 3 and 6 positions of the molecule. Substituents at the 
Rs and Rio positions on the T (tripyrrane) portion of the 
macrocycle are incorporated by appropriate functionaliza 
tion of carboxyl groups in the 5 positions of the tripyrrane 
at a synthetic step prior to condensation with a substituted 
ortho-phenylenediamine. 
In a method for synthesizing a texaphyrin metal complex 
having a substituent at the 2, 7, 12, 15, 18 or 21 position, the 
method comprises the steps of: i) mixing, in an organic 
Solvent, a nonaromatic texaphyrin having a substituent at the 
2, 7, 12, 15, 18 and/or 21 position, a trivalent metal salt, a 
Brønsted base and an oxidant; and ii) allowing the mixture 
to react to form an aromatic texaphyrin metal complex 











position. A preferred means is to stir at ambient temperature 
or heat the mixture at reflux for at least two hours. 
The corresponding nonaromatic texaphyrin having a sub 
stituent at the 2, 7, 12, 15, 18, and/or 21 position is 
conveniently produced by condensation of a tripyrrane alde 
hyde or ketone having structure A and a substituted ortho 
phenylenediamine having structure B: 
R4 R. R3 R. R. R A 
/ V / V / W R10 
N N N 





In this embodiment, R-R, R and Rs are independently 
hydrogen, halide. hydroxyl, alkyl, aryl, haloalkyl, nitro, 
formyl, acyl, hydroxyalkyl, oxyalkyl, oxyhydroxyalkyl, 
saccharide, carboxy, carboxyalkyl, carboxyamidealkyl, a 
site-directing molecule, or a couple to a site-directing mol 
ecule. 
R and R are independently selected from the groups of 
R-R, R and Rs with the proviso that the halide is other 
than iodide and the haloalkyl is other than iodoalkyl. 
Rs. Rio, R. and R2 are independently hydrogen, alkyl, 
aryl, hydroxyalkyl, oxyalkyl, oxyhydroxyalkyl, 
carboxyalkyl, carboxyamidealkyl or a couple to a saccharide 
or to a site-directing molecule. At least one of Rs. R. R. 
Rio R1 and R2 is other than hydrogen. 
In a preferred method of synthesis, the Brgonsted base is 
triethylamine or N.N,N',N'-tetramethyl-1.8- 
diaminonaphthalene ("proton sponge”), and the oxidant is 
air saturating the organic solvent, oxygen, platinum oxide, 
o-chloranil or 2,3-dichloro-5,6-dicyano-1,4-benzoquinone. 
The stirring or heating at reflux step may comprise stirring 
or heating at reflux the mixture for at least 24 hours. The 
organic solvent may comprise methanol, or methanol and 
chloroform, or methanol and benzene, or methanol and 
dimethylformamide. 
In the texaphyrins of the present invention, M is 
hydrogen, a divalent metal cation, or a trivalent metal cation. 
The divalent metal cation may be selected from, but is not 
limited to, the group consisting of Ca(II), Mn(II). Co(I), 
Ni(II), Zn(II), CdCI). Hg(II), Fe(II), Sm(II) and UO(II). 
The trivalent metal cation may be selected from, but is not 
limited to, the group consisting of Mn(III). Co(III), Ni(II), 
Fe(III). Ho(III), Ce(III), Y(III), In(III), Pr(III), NdCIII), 
Sm(III), Eu(III), Gd(III), Tb(III), Dy(III), Er(III), Tm(III), 
Yb(III), Lu(III), La(III), and U(III). 
The alkyl, aryl, hydroxyalkyl, oxyalkyl, 
oxyhydroxyalkyl, saccharide, carboxyalkyl, 
carboxyamidealkyl, site-directing molecule, or molecule 
couple is covalently bonded to the texaphyrin via a carbon 
carbon, a carbon-nitrogen or a carbon-oxygen bond. 
The aryl may be a phenyl group, unsubstituted or substi 
tuted with a nitro, carboxy, sulfonic acid, hydroxy, oxyalkyl 
or halide other than iodide substituent. In this case, the 
substituent on the phenyl group may be added in a synthetic 
step after the condensation step which forms the macrocycle. 
Representative examples of alkanes useful as alkyl group 




ethane, straight-chain, branched or cyclic isomers of 
propane, butane, pentane, hexane, heptane, octane, nonane 
and decane. with methane, ethane and propane being pre 
ferred. Representative examples of alkenes useful as alkenyl 
group substituents include ethene, straight-chain, branched 
or cyclic isomers of propene, butene, pentene, hexene, 
heptene, octene, nonene and decene, with ethene and pro 
pene being preferred. Representative examples of alkynes 
useful as alkynyl group substituents include ethyne, straight 
chain. branched or cyclic isomers of propyne, butyne, 
pentyne. hexyne, heptyne, octyne, nonyne and decyne, with 
ethyne and propyne being preferred. Representative 
examples of substituted alkyls include alkyls substituted by 
two or more functional groups as described herein. 
Among the halide substituents, chloride, bromide, fluo 
ride and iodide are contemplated in the practice of this 
invention with the exception that Rs and R are not iodide. 
R and R may have chloride, bromide or fluoride substitu 
ents. Representative examples of haloalkyls used in this 
invention include halides of methane, ethane, propane, 
butane. pentane, hexane, heptane, octane, nonane and 
decane, with halides, preferably chlorides or bromides, of 
methane, ethane and propane being preferred. 
Representative examples of hydroxyalkyls include alco 
hols of methane, ethane, straight-chain, branched or cyclic 
isomers of propane, butane, pentane, hexane, heptane, 
octane, nonane and decane, with alcohols of methane, 
ethane or propane being preferred. "Hydroxyalkyl" is meant 
to include glycols and polyglycols having hydroxyl groups; 
diols of ethane, straight-chain, branched or cyclic isomers of 
propane, butane, pentane, hexane, heptane, octane, nonane 
and decane, with diols of ethane or propane being preferred; 
polyethylene glycol, polypropylene glycol and polybutylene 
glycol as well as polyalkylene glycols containing combina 
tions of ethylene, propylene and butylene. 
Representative examples of oxyalkyls include the alkyl 
groups as herein described having ether linkages. The num 
ber of repeating oxyalkyls within a substituent may be up to 
100, preferably is from 1-10, and more preferably, is 2-3. A 
preferred oxyalkyl is O(CHCHO)CH, where x=1-100. 
preferably 1-10, and more preferably, 2-3. 
Representative examples of thioalkyls include thiols of 
ethane, thiols of straight-chain, branched or cyclic isomers 
of propane, butane, pentane, hexane, heptane, octane. 
nonane and decane, with thiols of ethane (ethanethiol, 
CHSH) or propane (propanethiol, CHSH) being pre 
ferred. Sulfate-substituted alkyls include alkyls as described 
above substituted by one or more sulfate groups, a repre 
sentative example of which is diethyl sulfate ((CH3)2SO). 
Representative examples of phosphates include phosphate 
or polyphosphate groups. Representative examples of 
phosphate-substituted alkyls include alkyls as described 
above substituted by one or more phosphate or polyphos 
phate groups. Representative examples of phosphonate 
substituted alkyls include alkyls as described above substi 
tuted by one or more phosphonate groups. 
Representative examples of carboxy groups include car 
boxylic acids of the alkyls described above as well as aryl 
carboxylic acids such as benzoic acid. Representative 
examples of carboxyamides include primary carboxyamides 
(CONH), secondary (CONHR) and tertiary (CONRR") 
carboxyamides where each of R and R" is a functional 
group as described herein. 
Representative examples of useful amines include a 












Hydroxyalkyl means alkyl groups having hydroxyl 
groups attached. Oxyalkyl means alkyl groups attached to an 
oxygen, Oxyhydroxyalkyl means alkyl groups having ether 
or ester linkages, hydroxyl groups, substituted hydroxyl 
groups, carboxyl groups, substituted carboxyl groups or the 
like. 
Saccharide includes oxidized, reduced or substituted sac 
charide; hexoses such as D-glucose, D-mannose or 
D-galactose; pentoses such as D-ribulose or D-fructose; 
disaccharides such as sucrose, lactose, or maltose; deriva 
tives such as acetals, amines, and phosphorylated sugars; 
oligosaccharides, as well as open chain forms of various 
sugars, and the like. Examples of amine-derivatized sugars 
are galactosamine, glucosamine, sialic acid and 
D-glucamine derivatives such as 1-amino-1-deoxysorbitol. 
Carboxyamidealkyl means alkyl groups containing any 
number of functional groups, one of which is a secondary or 
tertiary amide. Carboxyalkyl means alkyl groups containing 
any number of functional groups, one of which is a carboxyl 
group. 
For the above-described texaphyrins, oxyhydroxyalkyl 
may be alkyl having independently hydroxy substituents and 
ether branches or may be CH12OO, or OCo 
H12OO, where n is a positive integer from 1 to 10, 
x is zero or a positive integer less than or equal to n, and y 
is zero or a positive integer less than or equal to ((2n+1)-2x). 
The oxyhydroxyalkyl or saccharide may be CH-1 
OR OCHOR or (CH2)COR where n is a 
positive integer from 1 to 10, y is zero or a positive integer 
less than ((2n+1)-q), q is zero or a positive integer less than 
or equal to 2n+1, R is independently H. alkyl, 
hydroxyalkyl, Saccharide, CnH2n-1-2O, O, 
O2CCo-Hazn-1-2.O.O. or N(ROCCo-Ho-1-2) 
OO, where m is a positive integer from 1 to 10, w is zero 
or a positive integer less than or equal to m, Z is zero or a 
positive integer less than or equal to ((2m+1)-2w), R is H, 
alkyl, hydroxyalkyl, or C.H.O.R, where m is a 
positive integer from 1 to 10. Z is zero or a positive integer 
less than ((2m+1)-r), r is zero or a positive integer less than 
or equal to 2m+1, and R is independently H, alkyl, 
hydroxyalkyl, or saccharide. 
Carboxyamidealkyl may be alkyl having secondary or 
tertiary amide linkages or (CH2)CONHR'. O(CH), 
CONHR, (CH)NCONOR) or O(CH),CON(R) where 
n is a positive integer from 1 to 10, R is independently H, 
alkyl, hydroxyalkyl, Saccharide, Co-Ho-1-2.O.O. 
O2CCon-Ho-1-2.O.O. or N(R)OCCo-Ho-1-2) 
OO where m is a positive integer from 1 to 10, w is zero 
or a positive integer less than or equal to m, Z is Zero or a 
positive integer less than or equal to ((2m+1)-2w), R is H. 
alkyl, hydroxyalkyl, or CH2O, where m is a 
positive integer from 1 to 10, Z is zero or a positive integer 
less than ((2m+1)-r), r is zero or a positive integer less than 
or equal to 2m+1, and R is independently H, alkyl, 
hydroxyalkyl, or saccharide. 
The carboxyalkyl may be alkyl having a carboxyl substi 
tuted ether, an amide substituted ether or a tertiary amide 
removed from an ether or CHOR or OC 
H2OR where n is a positive integer from 1 to 10; 
y is zero or a positive integer less than ((2n+1)-q), q is zero 
or a positive integer less. than or equal to 2n+1. Rc is 
(CH),Co.R. (CH),CONHR or (CH),CONCR), where 
n is a positive integer from 1 to 10; R is independently H, 
alkyl hydroxyalkyl, Saccharide, C.-H.2.1-2O.O. 
O2CCon-Hazm-1-2.O.O. O N(R)OCCM-Ho-1-2) 
OO where m is a positive integer from 1 to 10, w is zero 
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or a positive integer less than or equal to m, Z is zero or a 
positive integer less than or equal to ((2m+1)-2w), R is H, 
alkyl hydroxyalkyl, or CHOR, where m is a 
positive integer from 1 to 10, z is zero or a positive integer 
less than ((2m+1)-r), r is zero or a positive integer less than 
or equal to 2m+1, and R is independently H, alkyl, 
hydroxyalkyl, or saccharide. 
A couple may be described as a linker, i.e., a reactive 
group for attaching another molecule at a distance from the 
texaphyrin macrocycle. An exemplary linker or couple is an 
amide, disulfide, thioether or ether covalent bond as 
described in the examples for attachment of oligonucleotides 
and antibodies. Certain reactions utilizing the texaphyrin 
complexes of the present invention, such as hydrolytic 
cleavage of phosphate ester bonds for example, by may be 
enhanced by additional catalytic groups appended to the 
texaphyrin metal complex or to a texaphyrin complex-site 
directing molecule conjugate. The term "catalytic group” 
means a chemical functional group that assists catalysis by 
acting as a general acid, Brønsted acid, general base, Brgin 
sted base, nucleophile, or any other means by which the 
activation barrier to reaction is lowered or the ground state 
energy of the substrate is increased. Exemplary catalytic 
groups contemplated include, but are not limited to, imida 
Zole; guanidine; substituted saccharides such as 
D-glucosamine, D-mannosamine, D-galactosamine, 
D-glucanine, and the like; amino acids such as L-histidine 
and L-arginine; derivatives of amino acids such as hista 
mine; polymers of amino acids such as poly-L-lysine, 
(LysAla)n or (LysLeuAla)n where n is from 1-30 or pref. 
erably 1-10 or more preferably 2-7, and the like; derivatives 
thereof; and texaphyrin metal complexes. The term 
"appended to the texaphyrin-site directing molecule conju 
gate means that the catalytic groups are attached either 
directly to the texaphyrin metal complex or to the texaphyrin 
complex via a linker or couple of variable length, or are 
attached to the ligand portion of a texaphyrin complex 
ligand conjugate either with or without a linker or couple of 
variable length. 
In one embodiment of the present invention, the texaphy 
rin is coupled to site-directing molecules to form conjugates 
for targeted in vivo delivery. "Specificity for targeted sites” 
means that upon contacting the texaphyrin conjugate with 
the targeted site, for example under physiological conditions 
of ionic strength, temperature, pH and the like, specific 
binding will occur. The interaction may occur due to specific 
electrostatic, hydrophobic, entropic or other interaction of 
certain residues of the conjugate with specific residues of the 
target to form a stable complex under conditions effective to 
promote the interaction. Exemplary site-directing molecules 
contemplated in the present invention include, but are not 
limited to: oligonucleotides, including oligodeoxyribonucle 
otides and oligoribonucleotide analogs; polyamides includ 
ing peptides having affinity for a biological receptor and 
proteins such as antibodies, low density lipoproteins, the 
APO protein of lipoprotein; steroids and steroid derivatives; 
hormones such as estradiol, or histamine; hormone mimics 
such as morphine; and further macrocycles such as sapphy 
rins and rubyrins. 
Representative examples of useful oligonucleotides 
include nucleotides, oligonucleotides and polynucleotides 
primarily composed of adenine, cytosine, guanine, thymine 
or uracilbases. An oligonucleotide may be derivatized at the 
base, the sugar, the ends of the chain, or at the phosphate 
groups of the backbone to promote in vivo stability. Modi 
fication of the phosphate groups is preferred in one embodi 









to nuclease activity. Preferred derivatives are 
methylphosphonates, phosphotriesters, phosphorothioates, 
and phosphoramidates, and the like. Additionally, phosphate 
linkages may be completely substituted with non-phosphate 
linkages such as amide linkages. Appendages to the ends of 
the oligonucleotide chain also provide exonuclease resis 
tance. Sugar modifications may include alkyl groups 
attached to an oxygen of a ribose moiety in a ribonucleotide. 
In particular, the alkyl group generally has 1 to 4 carbon 
atoms, and preferably is a methyl group and the methyl 
group is attached to the 2' oxygen of the ribose. Other alkyl 
groups may be ethyl or propyl. It is understood that the terms 
"nucleotide" and "oligonucleotide", as used herein, refer to 
both naturally-occurring and synthetic nucleotides, poly 
and oligonucleotides and to analogs and derivatives thereof. 
The term "texaphyrin-oligonucleotide conjugate" means 
that an oligonucleotide is attached to the texaphyrin in a 5' 
or a 3" linkage, or to both types of linkages to allow the 
texaphyrin to be an internal residue in the conjugate. The 
oligonucleotide or other site-directing molecule may be 
attached either directly to the texaphyrin via a linker, or a 
couple of variable length. During treatment, for example, the 
texaphyrin portion of a texaphyrin metal complex 
oligonucleotide conjugate of the present invention is envi 
sioned as being placed in the vicinity of the targeted tissue 
upon binding of the oligonucleotide to its complementary 
DNA or RNA 
Representative examples of useful steroids include any of 
the steroid hormones of the following five categories: 
progestins (e.g. progesterone), glucocorticoids (e.g., 
cortisol), mineralocorticoids (e.g., aldosterone), androgens 
(e.g., testosterone) and estrogens (e.g., estradiol). 
Representative examples of useful amino acids of pep 
tides or polypeptides include amino acids with simple ali 
phatic side chains (e.g., glycine, alanine, valine, leucine, and 
isoleucine), amino acids with aromatic side chains (e.g., 
phenylalanine, tryptophan, tyrosine, and histidine), amino 
acids with oxygen and sulfur-containing side chains (e.g., 
serine, threonine, methionine, and cysteine), amino acids 
with side chains containing carboxylic acid or amide groups 
(e.g., aspartic acid, glutamic acid, asparagine, and 
glutamine). and amino acids with side chains containing 
strongly basic groups (e.g., lysine and arginine), and proline. 
Representative examples of useful peptides include any of 
both naturally occurring and synthetic di-, tri-, tetra-, pen 
tapeptides or longer peptides derived from any of the above 
described amino acids (e.g., endorphin, enkephalin, epider 
mal growth factor, poly-L-lysine, or a hormone). Represen 
tative examples of useful polypeptides include both natu 
rally occurring and synthetic polypeptides (e.g., insulin, 
ribonuclease, and endorphins) derived from the above 
described amino acids and peptides. 
The term "a peptide having affinity for a biological 
receptor" means that upon contacting the peptide with the 
biological receptor, for example under appropriate condi 
tions of ionic strength, temperature, pH and the like, specific 
binding will occur. The interaction may occur due to specific 
electrostatic, hydrophobic, entropic or other interaction of 
certain amino acid or glycolytic residues of the peptide with 
specific amino acid or glycolytic residues of the receptor to 
form a stable complex under the conditions effective to 
promote the interaction. The interaction may alter the three 
dimensional conformation and the function or activity of 
either or both the peptide and the receptor involved in the 
interaction. A peptide having affinity for a biological recep 
tor may include an endorphin, an enkephalin, a growth 
factor, e.g. epidermal growth factor, poly-L-lysine, a 
5,756,726 
11 
hormone, a peptide region of a protein and the like. A 
hormone may be estradiol, for example. 
For the above-described texaphyrins, the couple may be 
an amide, disulfide, thioether or ether covalent bond; the 
oligonucleotide, the antibody, the hormone or the sapphyrin 
may have binding specificity for localization to a treatment 
site; and the biological receptor may be localized to a 
treatment site. 
Generally, water-soluble texaphyrins are preferred for the 
applications described herein. “Water-soluble" means 
soluble in aqueous fluids to about 1 mM or better. Such 
characteristics allow these texaphyrins to be useful in a 
biological environment. Improved water solubility can be 
achieved by, for example. substituents chosen from saccha 
rides or hydroxylated substituents. 
A preferred embodiment of the present invention is a 
texaphyrin wherein when either Rs or Ro is other than 
hydrogen, then R or R, respectively, is hydrogen, halide 
other than iodide (preferably fluoro), or hydroxyl. 
A further preferred embodiment of the present invention 
is a then Rs or Ro, respectively, is hydrogen or methyl. 
Other preferred functionalizations are where R and R. 
are hydrogen, then R. R. R. and R2 are aryl, lower alkyl 
or lower hydroxyalkyl. The lower alkyl is preferably methyl 
or ethyl, more preferably methyl. The lower hydroxyalkyl is 
preferably of 1 to 6 carbons and 1 to 4 hydroxy groups, more 
preferably 3-hydroxypropyl. The aryl is preferably phenyl, 
either unsubstituted or substituted, preferably unsubstituted. 
Further preferred embodiments of the present invention 
are where R and R are CHCH and R is CH, where Rs 
and Ro are methyl, or where R and Ro are (CH2)CH 
where n is 0. 1, 2, 3 or 4. Furthermore, Rs and Ro may be 
aryl having an R substituent where R is hydrogen, nitro, 
carboxy, sulfonic acid, hydroxy, oxyalkyl or halide. A pres 
ently preferred aryl is phenyl. The derivatization of the R 
group may occur after the condensation of the macrocycle. 
Preferred substituents for Rs include carboxy, alkyl or 
carboxyamidealkyl having a tertiary amide linkage. Pre 
ferred substituents for R. R. and R are oxyalkyl or 
hydroxyalkyl. 
Further preferred texaphyrins are wherein each of R-R 
is any one of the substituents of Tables A and B described 
herein below; more preferred texaphyrins are texaphyrins 
A1-A56 of Tables A and B described herein below. Pre 
ferred metals are Mn(II), Mn(III), Y(III), Lu(III). La(III), 
In(III), Gd(III), Eu(III), and Dy(III). 
Electron-donating substituents at the 2, 7, 12, 15, 18 
and/or 21 positions of the macrocycle stabilize the molecule 
against decomposition processes involving hydrolysis of the 
imine bonds. Such substituents also stabilize the resulting 
complex against demetallation by contributing electrons to 
the aromatic 7 system. Such electron-donating groups 
include hydroxyl, alkyl, haloalkyl other than iodoalkyl, aryl. 
hydroxyalkyl, oxyalkyl, oxyhydroxyalkyl, saccharide, 
carboxyalkyl, carboxyamidealkyl, a site-directing molecule, 
or a couple to any of these molecules. Hydrolysis-resistant 
texaphyrin metal complexes are useful for localization, 
magnetic resonance imaging, radiosensitization, radiation 
therapy, fluorescence imaging, photodynamic therapy and 
applications requiring singlet oxygen production for cyto 
toxicity. 
Electron-withdrawing substituents at the 15, 16, 17 and/or 
18 positions of the macrocycle destabilize the aromatic 1. 
system and render the macrocycle more readily reduced, i.e. 
more easily able to gain an electron to form a radical. Such 










iodide. formyl, acyl, carboxy, or nitro substituents. Readily 
reducible texaphyrin metal complexes are useful for radi 
osensitization where the extent of radiation damage is 
dependent on the generation of hydroxyl and texaphyrin 
radicals. 
The photophysical properties of prior texaphyrin metal 
complexes are reported in U.S. Pat. No. 5.252.720 and 
include strong low energy optical absorptions in the 
690-880 nm spectral range, a high triplet quantum yield and 
efficient production of singlet oxygen. Texaphyrin metal 
complexes of grandparent application Ser. No. 08/135.118. 
incorporated by reference herein, demonstrate enhanced 
cytotoxicity from radiation and enhanced nucleic acid strand 
scission in the presence of a gadolinium(III) metallotexa 
phyrin complex. U.S. Pat. No. 5.252.720 describes photo 
sensitized inactivation of enveloped viruses and magnetic 
resonance imaging (MRI) of atheroma, liver, kidney and 
tumor using various substituted texaphyrin metal com 
plexes. Altering the polarity and electrical charges of side 
groups of the texaphyrin macrocycles alters the degree, rate, 
and site(s) of binding to free enveloped viruses such as 
HIV-1 and to virally-infected peripheral mononuclear cells, 
thus modulating photosensitizer take-up and photosensitiza 
tion of leukemia or lymphoma cells contaminating bone 
marrow. Powerful techniques include the use of these texa 
phyrins in magnetic resonance imaging followed by 
photodynamic therapy in the treatment of atheroma and 
benign and malignant tumors, or followed by sensitized 
X-ray treatment. 
It is contemplated that the texaphyrins of the present 
invention will prove useful in a variety of applications. One 
example is in a method of deactivating a retrovirus or 
enveloped virus in an aqueous fluid. Such a method com 
prises the step of adding a texaphyrin metal complex having 
a substituent at the 2, 7, 12, 15, 18 and/or 21 position to said 
aqueous fluid and exposing the mixture to light to effect the 
formation of singlet oxygen. 
The aqueous fluid may be a biological fluid, blood, 
plasma, edema tissue fluid, ex vivo fluid for injection into 
body cavities, cell culture media, or a supernatant solution 
from cell culture and the like. 
In blood, an exemplary viral deactivating method would 
include: i) mixing with bloodinvitro or ex vivo a texaphyrin 
metal complex having a substituent at the 2, 7, 12. 15, 18 
and/or 21 position capable of producing singlet oxygen 
when irradiated in the presence of oxygen; and ii) photoir 
radiating the mixture in vitro or ex vivo to produce singlet 
oxygen in a quantity cytotoxic to said retrovirus or envel 
oped virus. Exemplary retroviruses or enveloped viruses 
include herpes simplex virus L. cytomegalovirus, measles 
virus, or human immunodeficiency virus HIV-1. However, it 
is contemplated that the utility of the invention is not limited 
to these viruses. Preferred metal cations are diamagnetic 
metal cations and a preferred metal complex is the Lu(III), 
La(TI) or In(III) complex of said texaphyrin. 
A further application of the present invention is a method 
of light-induced singlet oxygen production comprising sub 
jecting a texaphyrin metal complex having a substituent at 
the 2.7, 12, 15, 18 and/or 21 position to light in the presence 
of oxygen. A method of photosensitization comprising the 
production of singlet oxygen by irradiating a texaphyrin 
metal complex having a substituent at the 2, 7, 12, 15, 18 
and/or 21 position and an absorption range from about 730 
to about 770 nanometers to form long-lived triplet states in 
high yield is another embodiment of the present invention. 
A texaphyrin metal complex having a substituent at the 2, 7. 
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12, 15, 18 and/or 21 position has the structure as described 
previously herein; however, for these applications, M is a 
diamagnetic metal cation, for example. In(III), Zn(II), 
Cd(II), Lu(III) or La(III). "Intrinsic biolocalization selectiv 
ity" means having an inherently greater affinity for certain 
tissues relative to surrounding tissues. 
Further aspects of the present invention include the use of 
a texaphyrin paramagnetic-metal complex having a substitu 
ent at the 2, 7, 12. 15, 18 and/or 21 position in the following 
methods which take advantage of the high relaxivity of these 
compounds: i) a method of enhancement of relaxivity com 
prising the administration of said texaphyrin; ii) a method of 
magnetic resonance image enhancement comprising admin 
istering to a subject an effective amount of said texaphyrin; 
iii) a method of detection of neoplastic tissue in a patient 
comprising the steps of administering to a patient said 
texaphyrin in an amount effective to enhance a magnetic 
resonance image and detecting neoplastic tissue by magnetic 
resonance imaging of said patient; iv) a method of imaging 
an organ in a patient comprising administering to a patient 
said texaphyrin in an amount effective to enhance a magnetic 
resonance image of the organ and detecting the organ by 
magnetic resonance imaging of said patient (the organ may 
be liver, kidney or the upper GI tract); v) a method of 
imaging atheroma in a patient comprising administering to 
a patient said texaphyrin in an amount effective to enhance 
a magnetic resonance image of atheroma and detecting 
atheroma by magnetic resonance imaging of said patient. 
For use in these imaging applications, the texaphyrin 
paramagnetic-metal complex has the structure as described 
herein; however, M is a paramagnetic metal cation, such as 
a trivalent lanthanide metal other than La(III), Lu(III) and 
Pm(III). In particular, M may be Mn(II), Mn(III), Fe(III) or 
Gd(III) and is preferably Gd(III). 
A method of treating a host harboring atheroma or benign 
or malignant tumor cells is also an aspect of the invention. 
An exemplary preferred method includes administering to 
the host as a first agent a texaphyrin detectable-metal 
complex having a substituent at the 2, 7, 12, 15, 18 and/or 
21 position, said complex exhibiting selective biolocaliza 
tion in such atheroma or tumor cells relative to surrounding 
tissue; determining localization sites in the host by reference 
to such detectable metal; administering to the host as a 
second agent a texaphyrin diamagnetic-metal complex hav 
ing a substituent at the 2, 7, 12, 15, 18 and/or 21 position and 
having essentially identical biolocalization property and 
exhibiting the ability to generate singlet oxygen upon expo 
sure to light; and photoirradiating the second agent in 
proximity to said atheroma or tumor cells. 
In the above-described method, the first agent is further 
defined as being a texaphyrin paramagnetic-metal complex, 
the paramagnetic metal serving as the detectable metal. In 
this case, determination of localization sites occurs by 
magnetic resonance imaging; and the second agent is a 
texaphyrin diamagnetic-metal complex. The paramagnetic 
metal is most preferably Gd(III) and the diamagnetic metal 
is most preferably La(III), Lu(II) or In(III). A variation of 
this method uses as a first agent a texaphyrin-gamma emit 
ting metal complex that serves as a detectable metal, deter 
mination of localization sites occurs by gamma body scan 
ning and the second agent is a texaphyrin-diamagnetic metal 
complex. A further variation uses as a first agent a texaphy 
rin which exhibits fluorescence, e.g., a texaphyrin that is 
non-metallated (M=H) or is complexed with a diamagnetic 
metal. Localization means is then by fluorescent spectros 
copy, where M is hydrogen or a detectable metal, preferably 











ning or fluorescence spectroscopy. "Detectable" as used 
herein means that the location may be found by localization 
means such as magnetic resonance imaging if the metal is 
paramagnetic, gamma ray detection if the metal is gamma 
emitting or using monochromatic X-ray photon sources or 
by fluorescence. "Selective biolocalization" means having 
an inherently greater affinity for certain tissues relative to 
surrounding tissues. "Essentially identical biolocalization 
property" means the second agent is a texaphyrin derivative 
having about the same selective targeting characteristics in 
tissue as demonstrated by the first agent. 
A method of treating a host harboring tumor cells com 
prises the steps of: i) administering to the host an effective 
amount of a texaphyrin diamagnetic-metal complex having 
a substituent at the 2, 7, 12, 15, 18 and/or 21 position, the 
complex exhibiting selective biolocalization in the tumor 
cells relative to surrounding tissue; and ii) photoirradiating 
the texaphyrin-diamagnetic metal complex in proximity to 
the tumor cells. The photoirradiating is generally at a 
wavelength of about 730 to 770 nanometers or may be from 
laser light. In these embodiments, the diamagnetic metal will 
typically be InCIII), La(III) or Lu(III). 
The present invention provides a method of radiation 
therapy for a host harboring a tumor. The method includes 
the steps of administering to the host a texaphyrin having a 
substituent in the 2, 7, 12, 15, 18 and/or 21 position(s), and 
administering ionizing radiation to the host in proximity to 
the tumor either before or after administration of the 
texaphyrin, following procedures as described in U.S. Ser. 
No. 08/135.118, incorporated herein by reference. The texa 
phyrin exhibits greater biolocalization in the tumor relative 
to non-tumor tissue and has radiosensitization properties. A 
tumor may be a benign or malignant tumor or may be 
atheroma. A texaphyrin having radiosensitization properties 
enhances cytotoxicity from ionizing radiation as compared 
to control experiments without the texaphyrin. Ionizing 
radiation includes but is not limited to x-rays, and internal 
and external gamma emitting radioisotopes. 
The texaphyrin may be complexed with a metal; however, 
a metal is not necessary for radiosensitization. The metal is 
important to the stability of the texaphyrin complex. The 
ionizing radiation may be from an external source or the 
metal may be a radioactive metal. In the latter case, the 
ionizing radiation is from the radioactive metal in combi 
nation with radiation from an external source. 
An improved method of treating a host harboring a tumor 
comprises the further step of determining localization sites 
in the host by monitoring texaphyrin concentrations. "Moni 
toring texaphyrin concentrations” means measuring fluores 
cence of an administered free base texaphyrin or by refer 
ence to the metal of an administered texaphyrin metal 
complex. If the metal is paramagnetic, then magnetic reso 
nance imaging is used for measurement; if the metal is a 
gamma emitting radioactive metal, then gamma emission is 
used for measurement. 
A further improved method of treating a host harboring a 
tumor comprises the additional steps of administering to the 
host as a second agent a texaphyrin-diamagnetic metal 
complex having a substituent at the 2, 7, 12, 15, 18 and/or 
21 position and having essentially identical biolocalization 
property and administering ionizing radiation and photoir 
radiation in proximity to the tumor. 
In these methods, determining localization sites may 
occur by observing fluorescence from the texaphyrin. When 
the first agent is complexed with a metal, the metal may be 
a gamma-emitting metal and determining localization sites 
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would occur by gamma body imaging, or the metal may be 
a paramagnetic metal and determining localization sites 
would occur by magnetic resonance imaging. "Exhibiting 
greater biolocalization in the tumor relative to non-tumor 
tissue" means having an inherently greater affinity for tumor 
tissue relative to non-tumor tissue. The second agent has 
essentially identical biolocalization property as the first 
agent and exhibits the ability to generate singlet oxygen 
upon exposure to light. The photodynamic effect may be 
derived from anaerobic electron transfer processes. A pre 
ferred diamagnetic metal texaphyrin complex is the Lu(III), 
La(EEI) or InCIII) complex of a texaphyrin. "Essentially 
identical biolocalization property" means the second agent is 
a texaphyrin derivative having about the same selective 
targeting characteristics in tissue as demonstrated by the first 
agent. The first agent and the second agent may be the same 
texaphyrin. 
A preferred embodiment of the present invention is a 
method of radiation therapy for a host harboring a tumor 
comprising the steps of i) administering to the host a 
pharmaceutically effective amount of the Gd complex of a 
texaphyrin having a substituent at the 2, 7, 12, 15, 18 and/or 
21 position(s); and ii) administering ionizing radiation to the 
host in proximity to the tumor, either before or after admin 
istration of the texaphyrin metal complex. 
Another aspect of this invention is a method of imaging 
atheroma in a host comprising the administration to the host 
as an agent a detectable-metal texaphyrin complex having a 
substituent at the 2, 7, 12, 15, 18 and/or 21 position(s), said 
complex exhibiting selective biolocalization in such 
atheroma; and imaging the atheroma in the hostby reference 
to such detectable metal. The agent is preferably a 
detectable-metal texaphyrin complex having a paramagnetic 
metal serving as said detectable metal, and imaging of the 
atheroma occurs by magnetic resonance imaging. The para 
magnetic metal is preferably Gd(III). 
For the above-described uses, texaphyrins are provided as 
pharmaceutical preparations. A pharmaceutical preparation 
of a texaphyrin may be administered alone or in combination 
with pharmaceutically acceptable carriers, in either single or 
multiple doses. Suitable pharmaceutical carriers include 
inert solid diluents or fillers, sterile aqueous solution and 
various organic solvents. The pharmaceutical compositions 
formed by combining a texaphyrin of the present invention 
and the pharmaceutically acceptable carriers are then easily 
administered in a variety of dosage forms such as injectable 
solutions. 
For parenteral administration, solutions of the texaphyrin 
in sesame or peanut oil, aqueous propylene glycol, or in 
sterile aqueous solution may be employed. Such aqueous 
solutions should be suitably buffered if necessary and the 
liquid diluent first rendered isotonic using, for example, 
saline or glucose. These particular aqueous solutions are 
especially suitable for intravenous, intramuscular. subcuta 
neous and intraperitoneal administration. In this connection, 
sterile aqueous media which can be employed will be known 
to those of skill in the art in light of the present disclosure. 
The pharmaceutical forms suitable for injectable use 
include sterile aqueous solutions or dispersions and sterile 
powders for the extemporaneous preparation of sterile 
injectable solutions or dispersions. In all cases the form must 
be sterile and must be fluid to the extent that easy use with 
a syringe exists. It must be stable under the conditions of 
manufacture and storage and must be preserved against the 
contaminating action of microorganisms, such as bacteria 












containing, for example, water, ethanol, polyol (for example, 
glycerol, propylene glycol, and liquid polyethylene glycol, 
and the like), suitable mixtures thereof, and vegetable oils. 
The proper fluidity can be maintained, for example, by the 
use of a coating, such as lecithin, by the maintenance of the 
required particle size in the case of dispersion and by the use 
of surfactants. The prevention of the action of microorgan 
isms can be brought about by various antibacterial and 
antifungal agents, for example, parabens, chlorobutanol. 
phenol, sorbic acid, thimerosal, and the like. In many cases, 
it will be preferable to include isotonic agents, for example, 
sugars such as mannitol or dextrose or sodium chloride. A 
more preferable isotonic agent is a mannitol solution of 
about 2-8% concentration, and, most preferably, of about 
5% concentration. Prolonged absorption of the injectable 
compositions can be brought about by the use in the com 
positions of agents delaying absorption, for example, alu 
minum monostearate and gelatin. 
Sterile injectable solutions are prepared by incorporating 
the active compounds in the required amount in the appro 
priate solvent with various of the other ingredients enumer 
ated above, as required, followed by filtered sterilization. 
Generally, dispersions are prepared by incorporating the 
various sterilized active ingredients into a sterile vehicle 
which contains the basic dispersion medium and the 
required other ingredients from those enumerated above. In 
the case of sterile powders for the preparation of sterile 
injectable solutions, the preferred methods of preparation 
are vacuum-drying and freeze-drying techniques which 
yield a powder of the active ingredient plus any additional 
desired ingredient from a previously sterile-filtered solution 
thereof. 
As used herein, "pharmaceutically acceptable carrier" 
includes any and all solvents. dispersion media, coatings, 
antibacterial and antifungal agents, isotonic and absorption 
delaying agents and the like. The use of such media and 
agents for pharmaceutically active substances is well known 
in the art. Except insofar as any conventional media or agent 
is incompatible with the active ingredient, its use in the 
therapeutic compositions is contemplated. Supplementary 
active ingredients can also be incorporated into the compo 
sitions. 
The following examples describe the synthesis of texa 
phyrin metal complexes having a substituent(s) at the 2, 7, 
12, 15, 18 and/or 21 position(s) of the macrocycle. Unless 
defined otherwise, all technical and scientific terms used 
herein have the same meaning as commonly understood by 
one of ordinary skill in the art to which this invention 
belongs. Although any methods and materials similar or 
equivalent to those described herein can be used in the 
practice or testing of the present invention, the preferred 
methods and materials are now described. Unless mentioned 
otherwise, the techniques employed herein are standard 
methodologies well known to one of ordinary skill in the art. 
EXAMPLE 1. 
Synthesis of Compounds A3, A5, A6 and A7 
This example describes the synthesis of a texaphyrin 
metal complex having substituents at the 12(R). 15 (R). 18 
(R) and 21 (Rio) positions of the macrocycle as depicted in 
Scheme A. parts 1 and 2; a tripyrrane ketone A5, a substi 
tuted ortho-phenylenediamine A3, a nonaromatic texaphyrin 
A6, and a metal complex of aromatic texaphyrin A7. 
All solvents and reagents are of reagent grade quality, 
available commercially, and are used without further puri 
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fication. Sigma lipophilic Sephadex (LH-20-100) and 
Merck type 60 (230-400 mesh) silica gel are used for 
column chromatography. 
"H and 'C NMR spectra are obtained on a General 
Electric QE-300 (300 MHz.) spectrometer. Electronic spec 
tra are recorded on a Beckman DU-7 spectrophotometer in 
CHC. Infrared spectra are recorded, as KBrpellets, from 
4000 to 600 cm on a Nicolet 510PFT-IR spectrophotom 
eter. Chemical ionization mass spectrometric analyses (CI 
MS) are made using a Finnigan MAT 4023. Low resolution 
and high resolution fast atom bombardment mass spectrom 
etry (FABMS) are performed with a Finnigan-MATTSQ-70 
and VGZAB2E instruments, respectively. A nitrobenzyl 
alcohol (NBA) matrix is utilized with CHCl as the 
O 
18 
Tripyrrane ketone AS: An example of the synthesis of a 
precursor to a tripyrrane ketone, the 2,5-bis(3-(3- 
hydroxypropyl)-5-carboxyl-4-methylpyrrol-2-yl)methyl-3, 
4-diethylpyrrole F5, Scheme F, was presented in prior 
application, U.S. Ser. No. 08/135.118, incorporated by ref 
erence herein. In this example. R is 3-hydroxypropyl, R. 
and R are ethyl and R is methyl. 
The synthesis of compound F5 provides teachings for the 
synthesis of A4, precursor to tripyrrane ketone A5 as shown 
in Scheme F and described herein. 
co-solvent. Elemental analyses are performed by Atlantic 15 
Microlab, Inc. Melting points are measured on a Mel-temp 
apparatus and are uncorrected. 
Scheme A 
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diethylpyrrole. F3, Scheme F. In a 500 mL round bottom 
flask was placed 250 mL of ethanol from an unopened bottle 
which is purged with dry nitrogen for ten minutes. 3.4- 
Diethylpyrrole F2 (1.29 g, 0.01 mol) and 2-acetoxymethyl 
5 - be n z y l oxy car b on y 1 - 4 - m e thy 1 - 3 - 
methoxycarbonylethylpyrrole F1 (7.83 g, 0.02 mol) were 
added and the mixture heated until all of the pyrroles 
dissolved. p-Toluenesulfonic acid (65 mg) was added and 
the reaction temperature maintained at 60° C. The reaction 
slowly changed color from a clear yellow to a dark red with 
the product precipitating out of the solution as the reaction 
progressed. After ten hours the reaction was cooled to room 
temperature, the volume reduced to one half on a rotary 
evaporator, and then placed in the freezer for several hours. 
The product was collected by filtration, washed with a small 
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F5 
powder (61%): "H NMR (CDC1, 250MHz): 81.14 (6H, t, 
CHCH), 2.23 (6H, s, pyrrole-CH), 2.31 (4H, t, 
CHCHCOCH). 2.50 (4H, q, CHCH), 2.64 (4H, t, 
CHCH2COCH), 3.60 (10H, br s. CHCO- and 
(pyrrole)-CH2). 4.44 (4H, bris. CHCH), 6.99-7.02 
(4H, m, aromatic), 7.22-7.26 (6H. m., aromatic), 8.72 (1H. 
s, NH), 10.88 (2H, brs, NH); 'CNMR (CDC1,250MHz): 
8 10.97, 16.78, 17.71, 1940, 22.07, 35.09, 51.46, 65.32, 
117.37, 119.34, 122.14, 126.58, 126.79, 127.36, 128.19, 
133.55, 136.62, 162.35, 173.49; CIMS (M+H)+750; HRMS 
749.3676 (calc. for CHNOs: 749.3676). 
A synthetic scheme is presented in Scheme G for the 
attachment of an ester, a carboxyl and a tertiary amide as R2 
and R substituents. The synthesis of compound G1 is 
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2.5-Bis(5-benzyloxycarbonyl-3-(3-hydroxypropyl)-4- 
methylpyrrol-2-yl)methyl)-3,4-diethylpyrrole. F4, Scheme 
F. 2,5-Bis(5-benzyloxycarbonyl-4-methyl-3- 
methoxycarbonylethylpyrrol-2-yl)methyl-3,4- 
diethylpyrrole F3 (5.00 g, 0.007 mol) was placed in a three 
necked 100 mL round bottom flask and vacuum dried for at 
least 30 minutes. The flask was equipped with a 
thermometer, an addition funnel, a nitrogen inlet tube, and a 
magnetic stir bar. After the tripyrrane was partially dissolved 
into 10 mL of dry THF. 29 mL of borane (1MBH, in THF) 
was added dropwise with stirring. The reaction became 
mildly exothermic and was cooled with a cool water bath. 
The tripyrrane slowly dissolved to form a homogeneous 
orange solution which turned to a bright fluorescent orange 
color as the reaction went to completion. After stirring the 
reaction for one hour at room temperature, the reaction was 
quenched by adding methanol dropwise until the vigorous 
effervescence ceased. The solvents were removed under 
reduced pressure and the resulting white solid redissolved 
into CH2Cl2. The tripyrrane was washed three times with 
0.5M HCl (200 mL total), dried over anhydrous KCO, 
filtered, and the CHCl2 removed under reduced pressure 
until crystals of the tripyrrane just started to form. Hexanes 
(50M) was added and the tripyrrane allowed to crystallize 
in the freezer for several hours. The product was filtered and 
again recrystallized from CH.Clethanol. The product was 
collected by filtration and vacuum dried to yield 3.69 g of an 
orangish white solid (76%): mp 172°-173° C.; H NMR 
(CDC 300 MHz): 8 1.11 (6H, t, CHCH.), 1.57 (4H, p, 
CHCHCH-OH). 2.23 (6H. S. pyrrole-CH), 2.39-2.49 
(8H. m. CHCH and CHCHCH-OH), 3.50 (4H, t, 
CHCH2CH2OH), 3.66(4H; s, (pyrrole)-CH), 4.83 (4H, 
s, CH-CH), 7.17-7.20 (4H, m, aromatic), 7.25-7.30 
(6H, m, aromatic), 8.64 (IH, s, NH), 9.92 (2H, s, NH); 'C 
NMR (CDC1, 300 MHz): 8 10.97, 16.72, 17.68, 2000, 
22.38, 33.22, 62.01, 65.43, 117.20, 119.75, 120.72, 122.24. 
127.23, 127.62, 128.30, 132.95, 136.60, 162.13; FAB MS 
(M+) 693. 
2.5-Bis(3-(3-hydroxypropyl)-5-carboxyl-4-methyl 
pyrrol-2-yl) methyl-3,4-diethylpyrrole F5. Scheme F. 2.5- 
Bis((3-(3-hydroxypropyl)-5-benzyloxycarbonyl-4- 
methylpyrrol-2-yl)methyl-3,4-diethylpyrrole F4 (15.0 g. 











in vacuo for ca. 30 min. The tripyrrane was dissolved in dry 
THF (600 mL) with triethylamine (10 drops) and 10% Pd on 
carbon (600 mg) and the reaction was stirred at room 
temperature under one atmosphere of H. After 15 h, the 
suspension was filtered through celite to remove the catalyst 
and the resulting clear solution was concentrated under 
reduced pressure to yield a light pink solid. This material. 
obtained in near quantitative yield, was taken on to the next 
step without further purification, 
A carboxyl tripyrrane A4 (a specific example presented as 
F5 in Scheme F) (0.02 mol) is placed in a 250 mL round 
bottom flask and dried in vacuo for ca. 1 h. At room 
temperature under nitrogen, trifluoroacetic acid (31 mL, 
0.40 mol) is added dropwise via syringe. The tripyrrane 
dissolves with visible evolution of CO to form a homoge 
neous yellow solution. The reaction is stirred at room 
temperature for ca. 15 min, then cooled to 0°C. using a 
waterfice bath. A triethyl-ortho-ester (or trimethyl-ortho 
ester, ca. 18 eq) is added to the reaction mixture dropwise 
with stirring after which the reaction is stirred for an 
additional 15 minutes at 0° C. If the ester is acetate, then a 
methyl group would be attached, propionate would attach an 
ethyl group, for example. The reaction is warmed to room 
temperature and 100 mL of water added dropwise. After 
stirring the resulting two phase mixture for ca. 30 minutes, 
the reaction mixture is extracted three times with CHCI 
The CHCl extracts are combined and washed three times 
with 1M aq. NaHCO, once with water, dried over anhy 
drous sodium sulfate, filtered, and the solvent removed 
under reduced pressure. The resulting solid is recrystallized 
from CH2Clhexanes. 
Substituted ortho-phenylenediamine: The synthesis of an 
ortho-phenylenediamine substituted at the 4 and 5 positions 
is described in U.S. Pat. No. 5.252,720 and application Ser. 
No. 08/135,118. 
Texaphyrin macrocycles having a free carboxyl or a free 
amino group for further derivatization on the benzene ring 
portion of the molecule may be synthesized by replacing 
ortho-phenylenedianine with 3,4-diaminobenzoic acid or 
3,4-diaminoaniline. One skilled in the art of organic syn 
thesis would realize in light of the present disclosure that 
other substituted 1.2-o-phenylenediamines may be used as a 
precursor, e.g., a 1-2-o-phenylenediamine that is differen 
tially substituted in the 4 and 5 positions. This substitution 
may be the result of different functionalities being present or 
specific protection and standard organic and/or biochemical 
transformations having been carried out. Such macrocycles 
can be further functionalized to derivatives having an 
antibody, oligonucleotide. protein, peptide, sapphyrin and 
the like on one position of the B portion of the molecule. 
Synthesis of A3. Scheme A: Compound A1 of Scheme A 
(a 1.2-dialkyl-4,5-dinitrobenzene) is reacted with an alkyl 
halide where the halide is chloride, bromide or iodide in the 
presence of a Lewis acid such as AlCl, for example. The 3 
and 6 positions of the phenyl ring are derivatized with the 
alkyl group to form compound A2. A mixture of reactants 
having a single halide and different alkyl groups may be 
used to generate different alkyl derivatives at the 3 and 6 
positions. The yield of a particular product would be lower 
in this case. 
A diamine A3 (Scheme A) is obtained by reduction of the 
corresponding substituted dinitrobenzene (A2, Scheme A) 
with hydrazine hydrate (1 mL) and 10% palladium on 
carbon (50mg) in 40 mL refluxing absolute methanol. The 
resulting suspension may bubble for approximately 15-20 
minutes and then turn colorless after 1 hour. At this point the 
reduction is complete as verified by TLC. The reaction 
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solution is hot filtered through celite into a dry flask, covered 
with aluminum foil, and then concentrated to an oil. The 
diamine is taken to the next step without further purification. 
Ammonium formate in the presence of palladium (10% on 
carbon) catalyst may act as a mild, inexpensive and safe 
alternative to hydrazine hydrate in the above reaction and 
would be used, for example, when sensitive groups such as 
amide are present at other positions of the molecule. 
Condensation of a tripyrrane ketone and a substituted 
ortho-phenylenediamine to form a nonaromatic texaphyrin 
having substituents at the 2, 7, 12, 15, 18 and/or 21 position 
(s): A tripyrrane ketone and a substituted ortho 
phenylenediamine having substituents at the 3 and/or 6 
position(s) are placed in a 2 L round bottom flask with 1000 
mL of toluene and 200 mL of methanol. The solvents are 
purged with nitrogen prior to use. Concentrated HCl (0.5 
mL) is added and the reaction heated to reflux under 
nitrogen. After 5 h the reaction is cooled to room tempera 
ture and the solvents removed under reduced pressure until 
the product precipitates out of solution. The remainder of the 
solvent is decanted off and the macrocycle is dried in vacuo. 
The product is recrystallized from methanol/diethylether 
and characterized by "H NMR and 'C NMR. 
Condensation of a diformyltripyrrole and a substituted 
ortho-phenylenediamine yields a nonaromatic texaphyrin 
having substituents in the 15, 16, 17 or 18 positions. 
General procedure for the synthesis of a metal complex of 
texaphyrin (A7, Scheme A). One equivalent of the hydro 
chloride salt of the macrocycle A6, 1.5 equivalents of the 
M(OAc).XHO metal salt (where M=metal ion),and tri 
ethylamine (ca. 1 mL) are mixed together in methanol and 
heated to reflux under air. After completion of the reaction 
(as judged by the UV/vis spectrum of the reaction mixture), 
the solution is cooled to room temperature, the solvent is 
removed under reduced pressure and the crude complex 
dried in vacuo for several hours. A solution of 
dichloromethane/methanol (99:1 v?v) is added to the crude 
complex and the suspension is sonicated a few min. The 
suspension is filtered in order to remove impurities in the 
filtrate (incomplete oxidation products and excess 
triethylamine). The resulting solid is dissolved in methanol 
and then chloroform is added to reduce the polarity of the 
mixture (1:2 v/v). This solution is filtered through celite and 
loaded on a (pre-treated/pre-washed 1M NaNO) neutral 
alumina column (10 cm). The column is first eluted with a 
1:10 (v/v) methanol/chloroform solution by gravity to 
remove any impurity. The metal complex is then obtained by 
eluting the column with chloroform containing increasing 
amounts of methanol (20-50%). The purified lanthanide(III) 
texaphyrin complex is recrystallized by dissolving the com 
plex in methanol/chloroform and carefully layering the 
solution with a small amount of methanol, then with dieth 
ylether. The layered solution is kept at room temperature in 
the dark for a few days. The texaphyrin metal complex is 
recrystallized twice for analytically pure measurements and 
characterizations. 
Alternatively, the crude metal complex may be isolated by 
mixing the complex with an aqueous solution of a salt at a 
temperature above the freezing point of the resulting 
mixture, and then recovering the precipitated texaphyrin 
from the mixture. The salt can be any salt that is soluble in 
water or a waterforganic solvent mixture and does not cause 
transmetallation of the texaphyrin metal complex. 
The texaphyrin metal complex may alternatively be puri 
fied by dissolving the complex in water and methanol, and 











added to the solution. The mixture is agitated for a period of 
time and is then filtered to remove the zeolites. This proce 
dure may be repeated 2 or more times until significantly all 
of the free metal ion is removed. 
Lanthanum(III). Cerium(III). Praseodymium(III), 
Neodymium(III). Samarium(III), Europium(III), Gado 
linium (III), Terbium(III), Dysprosium(III). Holmium(III), 
Erbium(III), Thulium(III), Ytterbium(III), Lutetium(III) 
complexes of texaphyrin: The hydrochloride salt of macro 
cycle A6 (0.407 mmol), and one of the following lanthanide 
salts: La(OAc)6HO (0.814 mmol), Ce(OAc)6HO 
(0.611 mmol). Pr(OAc).5H2O (0.611 mmol), Nd(OAc) 
6HO(0.611 mmol), Sm(OAc).5H2O (0.611 mmol), 
Eu(OAc).5HO (0.65 mmol), Gd(OAc).5H2O (1.5 
mmol), Tb(OAc)6HO (0.611 mmol), Dy(OAc).5H2O 
(0.611 mmol), Ho(OAC3).5H2O (0.611 mmol). Er(OAc) 
5H2O (0.611 mmol), Tm(OAc).5H2O (0.611 mmol), 
Yb(OAc).5HO (0.611 mmol), or Lu(OAc)-HO (0.611 
mmol), together with TBANO (1.0 mmol) and triethy 
lamine (ca. 0.5 mL) in 350 mL methanol are heated to reflux 
under air for 5-24 h. The workup uses the general procedure 
outlined above. The thulium and lutetium complexes may be 
more difficult to purify due to their lower solubility in 
methanol/chloroform solutions, which leads to a lower yield. 
EXAMPLE 2 
Synthesis of Compounds B4, C5 and D5 
Ortho-phenylenediamine compounds having substituents 
bound to the phenyl ring via an oxygen are prepared as 
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2,3,4-Trihydroxybenzoic acid B1, is reacted with an alkyl 
5 halide where the halide is chloride, bromide, or iodide in 
the presence of potassium carbonate and acetonitrile to form 
a trialkoxy derivative B2. The alkyl group of the halide may 
be a primary or secondary alkyl having one or more 
hydroxy, alkoxy, carboxy, ester, amine, amide or protected 
amine substituents at positions at least one carbon removed 
from the site of halide attachment. These alkyl groups may 
be unsubstituted, singly or multiply functionalized. They 
may be branched or unbranched. Preferred alkyl groups are 
methyl, hydroxypropyl or methoxy(ethoxy)nethoxy 
(n=1-100; a polyethylene glycol substituent). Compound B2 
is reacted with 90% nitric acid to form the dinitro derivative 
B3 which is then reacted with either hydrazine hydrate or 
ammonium formate and 10% palladium on carbon in metha 
nol to form compound B4. 
In a similar synthesis, starting with 2,3,4- 
trihydroxybenzaldehyde C1 (Scheme C), reduction of the 







methyl derivative at the Rs position to form 1.2.3-trialkoxy 
4-methylbenzene C3. The diamine is formed as depicted in 
Scheme B and described above. 
Scheme D shows the formation of a tertiary amine at the 
Reposition. The starting material is 2,3,4-trihydroxybenzoic 
acid (D1). Compound D3 (B3) is treated with an amine 
component in 1,3-dicyclohexylcarbodiimide and dimethyl 
formamide to form D4 having an amide linkage. Alternative 
coupling reagents include 1,1-carbonyldiimidazole (CDI) or 
ECC. Reduction as described above yields the diamine for 
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Synthesis of a T2B4 Texaphyrin 
Scheme E, parts 1 and 2, shows the synthesis of a 
lanthanide metal complex of a T2B4 texaphyrin. A diformyl 
tripyrrole E5 is condensed with a substituted ortho 
phenylenediamine E4 to form the nonaromatic precursor E6. 
The synthesis of the substituted ortho-phenylenediamine E4 
was described in example 2 and the diformyltripyrrole was 
described in U.S. Pat. No. 5.252,720. In this example. R' 
may be polyethylene glycol (PEG) where the number of 
repeating ethoxy units may be as many as 200, a saccharide, 
a polyhydroxy substituent or the like. R may be methoxy, 
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EXAMPLE 4 of 12-o-phenylenediamines may be used to react with these 
w new functionalized tripyrranes. The organic synthesis 
Synthesis of E. Having Meso- required for the various transformations illustrated in 
Scheme A, parts 1 and 2, refers to the structure of a 60 
metallotexaphyrin with substituents in the 2 and 7 positions 
(meso-positions). Texaphyrin macrocycles having meso 
substitution on the periphery of the aromatic macrocycle 
may be synthesized by first preparing new methylene 
functionalized tyripyrrane dialdehydes described in Scheme 
I, parts 1 and 2. One skilled in the art of organic synthesis 
would realize in light of the present disclosure that a variety 
65 
Scheme I is derived from classic pyrrole/porphyrin chem 
istry. 
Synthesis of I3, Scheme I, part 1: Pyrrole I1(readily 
available from Aldrich Chemical Co., Milwaukee, Wis.) of 
Scheme I is reacted with sulfuryl chloride in 
dichloromethane, followed by hydrolysis with sodium 
acetate, and acidification to afford the acid pyrrole, 12 (see 
A. R. Battersby et al., J. C. S. Perkin I, 1976, 1008). 




Cyr, Ph.D. Dissertation, University of Texas at Austin. Commun. 1985. 1098-1100), in the presence of an aldehyde 
1992). (R =alkyl, aryl, etc.) will afford a mixture of three dipyr 
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Synthesis of I5. The acid-catalyzed condensation between 65 
compound I3 and the t-butylester derived pyrrole I4 (pyrrole romethanes. The desired mixed-ester derived dipyr 




preparation of dipyrromethanes is well-documented in the 
literature (see, Sessler et al., J. Org. Chem., 1986, 51.2838). 
Synthesis of I7. The t-butylester of compound I5 is 
selectively deprotected and decarboxylated via trifluoroace 
tic acid and subsequently condensed via acid-catalysis with 
pyrrole I3 in the presence of an aldehyde (R-alkyl, aryl, 
etc.) to afford the desired tripyrrane I7. 
Synthesis of the diformyl tripyrrane I9. With compound 
I7 in hand, the tripyrrane is transformed to the desired 
diformyl tripyrrane I9 (Rs-H) by standard organic synthesis 
reported earlier (U.S. Pat. No. 5.252,720). Compound I7 is 
reduced by borane/THF, followed by acetylation via acetic 
anhydride or acetyl chloride to afford tripyrrane I8. At this 
point, debenzylation of 18, followed by subsequent Clezy 
formylation of the intermediate, and basic hydrolysis with 
lithium hydroxide, provides tripyrrane I9. 
Tripyrrane I9 may then be condensed with an ortho 
phenylenediamine to construct a texaphyrin macrocycle as 
depicted in Scheme A. Substituents in these meso-positions 
are expected to further stabilize the macrocycle. 
EXAMPLE 5 
2.5-Bis(3-acetoxypropyl-5-benzoyl-4-methylpyrrol-2- 
yl)methyl-3,4-diethylpyrrole (J2). 2.5-Bis(3- 
acetoxypropyl-5-carboxyl- 4-methylpyrrol-2-yl)methyl)-3, 
4-diethylpyrrole J101.00 g. 1.67 mmol) was placed in a 100 
mL three-neck round-bottom flask and dried under high 
vacuum for ca. 1 hr. The round-bottom flask was equipped 
with an argon inlet line and for magnetic stirring. At room 
temperature under argon, CHCl (10 mL) was added to the 
flask and the resulting mixture stirred to form a suspension. 
Trifluoroacetic acid (2.7 mL) was then added all at once to 
the suspension. The tripyrrane dissolved to form a light 
orange solution. The reaction was stirred at room tempera 
ture under argon for ca. 45min, after which it was cooled to 
O C. using an ice/water bath. Triethylorthobenzoate (3.8 
mL) was added dropwise to the reaction with stirring over a 
two minute period under a flow of argon. The reaction was 
stirred for 40 min at 0° C. then allowed to warm to room 
temperature over 20 min. Water (20 mL) was added to the 
reaction and stirring continued for another 2 hr. Transferred 
reaction to a separatory funnel, separated and discarded the 
upper aqueous phase, and basified the lower organic layer 
with sat. aqueous NaHCO (Caution: gas evolution and 
frothing occurs). Separated the two layers and washed the 
organic phase once with sat. aqueous NaHCO and once 

















filtered off the drying agent, removed the solvent under 
reduced pressure, and dried the resulting orange-red oil 
under high vacuum overnight. The oil was dissolved into a 
minimum amount of CHCl (5-10 mL), the solution lay 
ered with hexanes (ca. 50 mL), and the tripyrrane allowed to 
crystallize at -20°C. The product was collected by filtration 
and dried under high vacuum to yield 1.06 grams of a tan 
solid (J2) (88%). "H NMR (CDC13,300 MHz): 81.06 (6H, 
t, CHCH), 1.67 (4H, p, CHCHCHOAc), 1.81 (6H, s, 
CHCO2-). 2.02 (6H. S., pyrr-CH-), 2.37-2.44 (8H, m, 
CHCH and CH2CH2CH2OAc), 3.71 (4H. s. (pyrr)- 
CH), 3.99 (4H. t. CHCHCHOAc), 7.29-7.48 (10H. m. 
aromatic), 9.16 (1H. s. NH). 9.66 (2H. s. NH); 'C NMR 
(CDC1): 8 11.8, 16.4, 17.7, 20.1, 20.9, 22.7, 29.1, 63.9, 
120.9, 121.5, 127.3, 128. 1, 128.2, 129.1, 130.8, 135.6, 
140.1, 171.3, 185.7; FAB MS, M: me 717. 
4.5-Diethyl-9.24-bis(3-hydroxypropyl)-16, 17 
dimethoxy-1023-dimethyl-12,21-diphenyl-13.20.25.26. 27-pentaazapentacyclo-20.2.1.1.1'0' heptacosa-3. 
5,8,10,12,14.16, 1820.22.24-undecaene (J6). 2.5-Bis(3-acetoxypropyl-5-benzoyl-4-methylpyrrol-2-yl) 
methyl-3,4-diethylpyrrole J2 (100 mg. 0.14 mmol) and 
4.5-dimethoxy-12-phenylenediamine J5 (23 mg 0.14 
mmol) were dissolved into 100 mL of absolute methanol 
under argon. Concentrated HCl (5 drops) was added and the 
reaction heated at reflux under argon. After heating for 2 
days, the reaction was cooled to room temperature and the 
solvent removed under reduced pressure. The resulting red 
solid was dissolved into CHCl (5 mL), filtered, and the 
CHCl solution layered with hexanes (20 mL). The product 
was allowed to slowly precipitate out of solution at room 
temperature overnight. The mother liquor was decanted off 
and the remaining solid washed with hexanes. After drying 
the solid under high vacuum, 39 mg of dark red product (J6) 
was obtained. FAB MS. (M--H): me 766. 
Cadmium(II) complex of 4.5-diethyl-9.24-bis(3- 
hydroxypropyl)-16,17-dimethoxy-10,23-dimethyl-1 2.21 diphenyl-1320,25,26.27-pentaazapentacyclo[20.2.1.1.1 
11.0'-heptacosa-1,3,5,7,9,11(27). 12.14(19), 15, 17.2022 
(25).23-tridecaene (J8). The protonated form of the 
macrocycle Jé (11 mg, 0.014 mmol), cadmium(II) chloride 
(11 mg, 0.06 mmol) and triethylamine (20 mL) in 20 mL of 
methanol were heated at reflux under air for 2 days. The 
reaction was cooled to room temperature, the solvent 
removed under reduced pressure, and the complex dried in 
vacuo overnight to give the final texaphyrin-Cd(II) metal 
complex (J8). UV/vis (CHOH) A nm): 472.0, 756.0; 
FAB. MS, (M+H)": m/e 875. 
1) trifluoroacetic acid 













-3,4-diethylpyrrole (J4). 2.5-Bis(5-carboxyl-3-ethyl-4- 
methylpyrrol-2-yl)methyl)-3,4-diethylpyrrole J3 (1.00 g, 
2.20 mmol) was placed in a 100 mL three-neck round 
bottom flask and dried under high vacuum for 1 hr. The 
round-bottom flask was equipped with an argon inlet line 
and for magnetic stirring. At room temperature under argon. 
CH2Cl2 (10 mL) was added to the reaction flask and the 
resulting mixture stirred to form a suspension. Trifluoroace 
tic acid (3.5 mL) was then added all at once to the suspen 
sion. The tripyrrane dissolved to form a yellowish orange 
solution. The reaction was stirred at room temperature under 
argon for ca. 35min, after which it was cooled to 0°C. using 
an ice/water bath. Triethylorthobenzoate (5.0 mL) was 
added dropwise to the reaction with stirring over a two 
minute period under a flow of argon. The reaction was 
stirred for 40 min at 0° C. then allowed to warm to room 
temperature over 20 min. Water (20 mL) was added to the 
reaction and stirring continued for another 1 hr. Transferred 
reaction to a separatory funnel, separated and discarded the 
upper aqueous phase, and basified the lower organic layer 
with sat aqueous NaHCO (30 mL) (Caution: gas evolution 
and frothing occurs). Separated the two layers and washed 
the organic phase once with sat aqueous NaHCO and once 
with water. Dried organic phase over anhydrous MgSO4, 
filtered off the drying agent, and removed the solvent under 
reduced pressure to yield a dark oil with some precipitate. 
The oil and solid were dissolved into a minimum amount of 
CHCl2 (5 mL), the solution layered with hexanes (ca. 50 
mL), and the product allowed to crystallize at -20° C. The 
product was collected by filtration, washed with a small 
amount of hexanes, and dried under high vacuum to yield 





MHz): 8 0.95 (6H, t, CHCH), 1.05 (6H, t, CHCH.). 1.80 
(6H, s, pyrr-CH). 2.32-2.40 (8H. m. CHCH), 3.67 (4H, 
s, (pyrr)-CH), 7.27-7.48 (10H, m, aromatic), 9.27 (1H, 
s, NH), 9.66 (2H. S. NH); 'CNMR (CDC1): 8 11.7.15.1, 
16.3, 17.1, 17.7. 22.8, 120.8, 121.4. 124.8, 127.0, 128.0(6), 
128.1(4). 129.2, 130.6, 135.5, 140.2, 185.7; FAB MS. 
(M+H)": me 574. 45.9.24-Tetraethyl-16,17-dimethoxy-10.23-dimethyl-12, 
21-diphenyl-13.20.25.26.27-pentaazapentacyclo (20.2.1.1.1'.0']heptacosa-3.5.8.10.12.14.16, 18.20, 
22.24-undecaene (J7). 2.5-Bis(5-benzoyl-3-ethyl-4- 
methylpyrrol-2-yl)methyl-3,4-diethylpyrrole J4 (101 mg, 
0.18 mmol) and 4.5-dimethoxy-1,2-phenylenediamine J5 
(30 mg, 0.18 mmol) were dissolved into 200 mL of toluene 
and 100 mL of absolute methanol. The solvents were 
sparged with argon for approximately 5 min before the 
reaction was started. Concentrated HCl (3 drops) was then 
added and the reaction heated at reflux under an atmosphere 
of argon. After heating for ca. 2.75 days, the reaction was 
cooled to room temperature, the solvent removed under 
reduced pressure and the remaining solid dried in vacuo. The 
macrocycle was dissolved into CHCl (10 mL), filtered, 
and the CHCl solution layered with hexanes (80 mL). The 
product was allowed to slowly precipitate out of solution at 
-20° C. overnight. The macrocycle was collected by 
filtration, dissolved into a minimum amount of ethanol, and 
the solution layered with hexanes. The macrocycle was 
allowed to slowly precipitate out of solution at -20° C. for 
several days. The macrocycle was collected by filtration, 
washed with a small amount of hexanes, and dried under 
high vacuum to yield 28 mg of dark red product (J7). FAB 
MS, (M+H)": me 707. 
Macrocycle J7 can be oxidized and metallated to give the 
corresponding texaphyrin metal complex following the pro 
cedures previously described herein. 
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R. R. R. and/or Rio Substituents 
Scheme H. parts 1 and 2, shows a synthetic scheme for 
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R = R = polyethylene glycol (PEG), n = 1-200; saccharide, polyhydroxy 
A 1.2-dialkyl-4,5-dinitrobenzene (H1, also A1) is reduced 
with ammonium formate to the diamino derivative and an 
amine protecting group is attached before the nitration step. 
Amine protecting groups include amides such as N-acetyl. 
and carbamates such as CBZ, for example. An acetyl pro 
tecting group is later removed by refluxing in HCl. Protec 
tion and deprotection procedures are well known to those of 
skill in the art in light of the present disclosure (Greene et al. 
1991). The deprotected nitro derivative H5 is condensed 
with a diformyltripyrrane H6 to form a nonaromatic texa 
phyrin having a nitro group at the 15 position. 
A bromine is introduced at the RandR positions of the macrocycle by reacting 1.2-dialkyl-4,5-dinitrobenzene with 
bromine in the presence of FeBr or AlBr. The 3 and 6 
so positions of the phenyl ring are derivatized with bromide 
and reduction to the amine as described in example 2 
prepares the precursor for condensation with a diformyl 
tripyrrole or a tripyrrane ketone. 
Preferred texaphyrins having a substituent on the 2, 7, 12, 
15, 18 and/or 21 position of the macrocycle are listed in 
65 Tables A and B. Substituents R-Rs are provided in Table A 







Representative Substituents for Texaphyrin Macrocycles Al-A50 of the Present Invention. 
Substituents for R. Ra Are Provided in TABLE A and for RI-R in TABLE B. 
TXP R Rs R2 Rio R R2 
AS p O(CH2)CON-linker-oligo p 
A6 H OCHCON-linker-oligo OCH, k 8 
A7 OCHCO-poly-L-lysine s 
A8 : OCHCO-estradiol y 
A9 p O(CHCHO)CH 
A10 O(CHCHO)CH, s I 4. 
All it. OCHCON-linker-oligo e 
A12 By OCHCO-estradiol w 
A3 p O(CHCHO)CH, O(CHCHO)CH s t 
A14 9 OCHCO-estradiol 
A15 O(CH2CH2O)CH O(CH2CH2O)2CH OCH, w 
A16 H saccharide I9 g 
A17 O(CHOH O(CH)OH H CH, 
A18 H O(CHCHO)CH w y 
A19 O(CHCHO)CH, w U 
A20 H OCHCON-linker-oligo H CH, 
A21 OCHCO-estradiol 4. I 
A22 OCHCON(CHCH-OH), I 
A23 O(CHCHO)CH O(CHCHO)2CH y 
A24 OCH2CON-linker-oligo FI 
A25 H CHCON(CHCH p t o 
(CHOH)CHOH 
A26 O(CHCHO)CH O(CHCHO)CH, OH y 
A27 w F 
A28 9. Iv H CH(CH2)6OH 
A29 p Br H 
A30 g NO, 
A31 COOH 
A32 t CH, t B 
A33 H CHs y 
A34 P CHCH g 
A35 t CH e 
A36 w p 
A3 OCH, OCH w p g 
A38 H OCH2CO-glucosamine CH(CHOH w 
A39 O(CH)OH O(CH)OH H CH, CH, CH 
of Oy or 
CHCH CHCH CHCH 
A40 O(CHCHO)CH O(CHCHO)CH p 
A41 O(CHOH O(CHCHO)CH, g 
A42 H O(CH2)CON-linker-oligo, p p 
n = 1,2,3 
A43 H O(CH2)CO-estradiol, t 
n = 1,2,3 
A44 H saccharide 
A45 O(CH2OH O(CH2)CON-linker-oligo, 
n = 1,2,3 
A46 O(CH2)CO-estradiol, y y 
n = 1,2,3 
A47 y saccharide 
A48 O(CHCHO)CH O(CH2)CON-linker-oligo, s w 
rl = 1,2,3 
A49 v O(CH2)CO-estradiol, t 
n = 1,2,3 
A50 saccharide I I 
A51 O(CH)CON-linker-oligo H 
n = 1,2,3 
A52 O(CHCHO)CH 
AS3 y w Ot p CH(CH),OH CH(CH)OH 
AS4 O(CH)CON-linker-oligo J. 
n = 1,2,3 
ASS CH, or I 
CHCH, 
A56 O(CHCHOCH, w up 
60 
hydroxyalkyl and like. as described in U.S. Pat. No. 5.252, 
720 and application Ser. No. 08/135,118. 
EXAMPLE 8 
65 Further Derivatives of Texaphyrin 
One skilled in the art of organic synthesis in light of the 
present disclosure could extend and refine the basic syn 
A substituent on the Rs. Rio, R or R2 position of the 
macrocycle may be derivatized after condensation of the 
macrocycle. Substituents may include an alkyl group having 
up to 5 carbonatoms or a phenyl group which may be further 
derivatized with a nitro, carboxyl, sulfonic acid, hydroxyl, 
halide or alkoxy where the alkyl of the alkoxy may be 
5,756,726 
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thetic chemistry outlined in this application, in U.S. Pat. No. 
5.252,720 and in application Ser. No. 08/135,118 so as to 
produce texaphyrins having various substituents, yet having 
basic utility to those specifically detailed in the present 
examples. For example, polyether-linked polyhydroxylated 
groups, catechol (i.e. benzene diol) derivatives bearing fur 
ther hydroxyalkyl substituents off the tripyrrane-derived 
portion of the macrocycle, saccharide substitutions in which 
the saccharide is appended via an acetal-like glycosidic 
linkage, an oligosaccharide or a polysaccharide may be 
similarly linked to a texaphyrin. A doubly carboxylated 
texaphyrin in which the carboxyl groups are linked to the 
texaphyrin core via aryl ethers or functionalized alkyl sub 
stituents could be converted to various esterified products 
wherein the ester linkages serve to append further hydroxyl 
containing substituents. Polyhydroxylated texaphyrin 
derivatives may be synthesized via the use of secondary 
amide linkages. Saccharide moieties may be appended via 
amide bonds. Polyhydroxylated texaphyrin derivatives con 
taining branched polyhydroxyl (polyol) subunits may be 
appended to the texaphyrin core via aryl ethers or ester 
linkages. 
Treatment of carboxylated texaphyrins with thionyl chlo 
ride or p-nitrophenol acetate would generate activated acyl 
species suitable for attachment to monoclonal antibodies or 
other biomolecules of interest. Standard in situ coupling 
methods (e.g. 1.1'-carbonyldiimidazole (CDI)) could be 
used to effect the conjugation. 
The selectivity of the texaphyrins may be enhanced by 
covalently linking oligonucleotides onto the periphery of the 
macrocycle. Amides, ethers and thioethers are representative 
of linkages which may be used for this purpose. Oligonucle 
otides functionalized with amines at the 5'-end, the 3'-end, or 
internally at sugar or base residues may be modified post 
synthetically with an activated carboxylic ester derivative of 
the texaphyrin complex. Alternatively, oligonucleotide ana 
logs containing one or more thiophosphate or thiol groups 
may be selectively alkylated at the sulfur atom(s) with an 
alkyl halide derivative of the texaphyrin complex. The 
resultant oligodeoxynucleotide-texaphyrin complex conju 
gates may be designed so as to provide optimal catalytic 
interaction between a target nucleic acid and the bound 
texaphyrin. The oligonucleotide may be large enough to 
bind probably at least 15 nucleotides of complementary 
nucleic acid. 
A general method for preparing oligonucleotides of vari 
ous lengths and sequences is described by Caracciolo et al. 
(1989). Preferred oligonucleotides resistant to in vivo 
hydrolysis may contain a phosphorothioate substitution at 
each base (J. Org. Chem., 55:4693-4699, 1990). Oligode 
oxynucleotides or their phosphorothioate analogues may be 
synthesized using an Applied Biosystem 380B DNA syn 
thesizer (Applied Biosystems, Inc.. Foster City, Calif.). 
Specific methods for preparing texaphyrin-oligonucleotide 
conjugates are disclosed in PCT publication WO94,29316, 
the disclosure of which is incorporated herein by reference. 
Another means of gaining selectivity may be to covalently 
link the texaphyrin complex to a sapphyrin (sap) molecule, 
(U.S. Pat. No. 5,159,065; U.S. Pat. No. 5,120,411; U.S. Pat, 
No. 5,041.078, all incorporated by reference herein.) Since 
sapphyrins bind DNA, K-10 M. (U.S. Ser. No. 07/964, 
607, incorporated by reference herein) the linked 
texaphyrin-sapphyrin complex (txph-sap) could effectively 
increase the texaphyrin concentration at locations adjacent 
to the sapphyrin binding sites. Sapphyrins have a higher 
fluorescent quantum yield than texaphyrins, allowing greater 












where the molecules are optimized to the laser wavelength; 
an excited sapphyrin may transfer its energy to the conju 
gated texaphyrin for detection. The texaphyrin molecule 
may further be designed to pass through cell membranes for 
selective radiosensitization. 
New texaphyrin derivatives are characterized fully using 
normal spectroscopic and analytical means, including. X-ray 
diffraction methods. 
It is understood that the examples and embodiments 
described herein are for illustrative purposes only and that 
various modifications in light thereof will be suggested to 
persons skilled in the art and are to be included within the 
spirit and purview of this application and scope of the 
appended claims. 
What is claimed is: 
1. A method of producing light-induced singlet oxygen, 
the method comprising subjecting a texaphyrinto light in the 




M is a diamagnetic metal cation; 
R-R. R. and Rs are independently hydrogen, halide, 
hydroxyl, alkyl, aryl, haloalkyl. nitro, formyl, acyl, 
hydroxyalkyl, oxyalkyl, oxyhydroxyalkyl, saccharide, 
carboxy, carboxyalkyl, carboxyamidealkyl, a site 
directing molecule, a catalytic group, or a couple to a 
site-directing molecule or to a catalytic group; 
Rs and R are independently selected from the groups of 
R-R. R. and Rs, with the proviso that the halide is 
other than iodide and the haloalkyl is other than 
iodoalkyl; 
Rs and Ro-R2 are independently hydrogen, alkyl, aryl, 
hydroxyalkyl, oxyalkyl, oxyhydroxyalkyl, 
carboxyalkyl, carboxyamidealkyl or a couple to a 
saccharide, to a site-directing molecule or to a catalytic 
group; 
at least one of R. R. R. R. R. and R2 is other than 
hydrogen; and 
Z is an integer less than or equal to 5. 
2. The method of claim 1 where the paramagnetic metal 
cation is selected from the group consisting of CdCII), Zn(II). 
In(III), Y(III). La(III), and Lu(II). 
3. The method of claim 1 where the light has a wavelength 
range from about 730 to about 770 nm. 
4. The method of claim 1 where the couple is an amide. 
disulfide, thioether or ether covalent bond. 
5. The method of claim 1 where the catalytic group is 




substituted saccharides, amino acids, derivatives of amino 
acids, polymers of amino acids, and texaphyrin metal com 
plexes. 
6. The method of claim 1 where the site-directing mol 
ecule has binding specificity for localization to a treatment 
site. 
7. The method of claim 1 where the site-directing mol 
ecule is selected from the group consisting of an 
oligonucleotide, an antibody, a hormone. a hormone mimic, 
a peptide having affinity for a biological receptor, and a 
sapphyrin molecule. 
8. The method of claim 1 where at least one of Rs and 
Ro-R is other than hydrogen; and 
when Rs is other than hydrogen, then R is hydrogen, 
halide other than iodide, or hydroxyl; and 
when Rio is other than hydrogen, then R is hydrogen, 
halide other than iodide, or hydroxyl. 
9. The method of claim 1 where at least one of R and R. 





when Rs is other than hydrogen, then R is hydrogen or 
methyl; and 
when R is other than hydrogen, then Rio is hydrogen or 
methyl. 
10. The method of claim 1 where Rs and Ro are aryl 
having an R substituent where R is hydrogen, nitro, 
carboxy, sulfonic acid, hydroxy, oxyalkyl or halide. 
11. The method of claim 1 where each of R-R is any 
one of the substituents for R-R set out in Tables A and B. 
12. The method of claim 1 where R is CH(CH)OH. R. 
and R are CHCH. R. Rs and Ro are CHR and R are 
H. and R, and Rs are O(CHCHO)CH or R is H or 
OCH and Rs is a site-directing molecule or a couple to a 
site-directing molecule. 
13. The method of claim 12 where R and R are H or 
CH 
14. The method of claim 1 where the texaphyrin is 
selected from texaphyrins A1-A56 of Tables A and B. 
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